Genentech announced that the Food and Drug Administration (FDA) has approved Lucentis (ranibizumab injection) 0.5mg prefilled syringe (PFS) as a new method of administration to treat both wet age-related macular degeneration (AMD) and macular edema after retinal vein occlusion (RVO).
Lucentis, a vascular endothelial growth factor (VEGF), was already approved as a 0.5mg vial in 2006 to treat wet AMD and in 2010 to treat macular edema after RVO. This approval makes Lucentis the first anti-VEGF pre-filled syringe to treat both eye conditions. The PFS eliminates several steps in the preparation process for the physician. With the Lucentis PFS, physicians attach the injection needle to the syringe and adjust the dose prior to administration.
The Lucentis 0.5mg PFS is expected to be available in early 2017.
For more information visit Genentech.com.